S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:AMGN

Amgen (AMGN) Stock Forecast, Price & News

$266.31
-2.45 (-0.91%)
(As of 04:00 PM ET)
Compare
Today's Range
$264.38
▼
$268.49
50-Day Range
$230.41
▼
$271.46
52-Week Range
$211.71
▼
$296.67
Volume
1.90 million shs
Average Volume
2.45 million shs
Market Capitalization
$142.45 billion
P/E Ratio
17.96
Dividend Yield
3.20%
Price Target
$265.44
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Amgen MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
0.4% Upside
$266.69 Price Target
Short Interest
Healthy
1.17% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
1.04mentions of Amgen in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$30 M Bought Last Quarter
Proj. Earnings Growth
8.61%
From $18.35 to $19.93 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.88 out of 5 stars

Medical Sector

51st out of 969 stocks

Biological Products, Except Diagnostic Industry

5th out of 161 stocks

See Top Rated MarketRank™ Stocks Here

AMGN stock logo

About Amgen (NASDAQ:AMGN) Stock

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

AMGN Price History

AMGN Stock News Headlines

September 25, 2023 | marketbeat.com
Argenx's 28% Surge & Promising Product Propel Investor Confidence (AMGN)
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
September 20, 2023 | marketbeat.com
Flee to Healthcare Stocks if Recession Rears its Head? (AMGN)
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
October 2, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
September 6, 2023 | marketbeat.com
3 Growth Stocks to Buy in September (AMGN)
As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earnings
September 30, 2023 | msn.com
Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Weren't.
September 28, 2023 | markets.businessinsider.com
DBS Remains a Buy on Amgen (AMGN)
September 27, 2023 | proactiveinvestors.com
Neumora Therapeutics stock surges as Amgen confirmed as major shareholder
September 27, 2023 | finance.yahoo.com
Amgen Could Get a Piece of the Obesity Market
October 2, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
September 25, 2023 | markets.businessinsider.com
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
September 25, 2023 | finance.yahoo.com
Dow Jones Biotech Giant Amgen, Meta Stock, Eye Buy Points In Stock Market Correction
September 23, 2023 | finance.yahoo.com
The Hedge Fund That Made a Killing Betting Against Lina Khan
September 21, 2023 | finance.yahoo.com
Amgen (AMGN) Stock Moves -0.76%: What You Should Know
September 21, 2023 | finance.yahoo.com
Why Shares of Neumora Therapeutics Slumped This Week
September 20, 2023 | finance.yahoo.com
AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS
September 20, 2023 | finance.yahoo.com
Amgen (AMGN)'s True Worth: A Complete Analysis of Its Market Value
September 20, 2023 | msn.com
IBM, Amgen share gains contribute to Dow's nearly 200-point jump
September 20, 2023 | msn.com
Dow's nearly 100-point rally led by gains for shares of Amgen, IBM
September 20, 2023 | finance.yahoo.com
Best Dividend Stocks: Amgen Hits Buy Point, Offers Solid Dividend Growth
September 19, 2023 | finance.yahoo.com
FTC chair targets deals that have fallen in agency's 'blind spots'
September 19, 2023 | finance.yahoo.com
Healthcare: FTC Chair Lina Khan to crack down on 'below radar' deals
September 15, 2023 | benzinga.com
Amgen Unusual Options Activity
September 14, 2023 | stocknews.com
Moderna (MRNA) Stock Analysis: Is the Biotech Stock a Buy at This Time?
September 14, 2023 | investing.com
Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines' $273 million fundraise
September 14, 2023 | finance.yahoo.com
Amgen-partnered AI biotech startup brings in $273M
September 14, 2023 | finance.yahoo.com
Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines' $273 mln fundraise
September 14, 2023 | finance.yahoo.com
Should You Consider Selling Amgen (AMGN)?
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Company Calendar

Last Earnings
8/03/2023
Ex-Dividend for 9/8 Dividend
8/17/2023
Dividend Payable
9/08/2023
Today
10/02/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
CIK
318154
Web
www.amgen.com
Phone
(805) 447-1000
Fax
805-447-1010
Employees
25,200
Year Founded
1980

Price Target and Rating

Average Stock Price Forecast
$265.44
High Stock Price Forecast
$320.00
Low Stock Price Forecast
$200.00
Forecasted Upside/Downside
+0.3%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
15 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$14.83
Trailing P/E Ratio
17.84
Forward P/E Ratio
14.42
P/E Growth
3.38
Net Income
$6.55 billion
Net Margins
30.02%
Pretax Margin
34.60%
Return on Equity
196.60%
Return on Assets
12.42%

Debt

Debt-to-Equity Ratio
8.76
Current Ratio
2.77
Quick Ratio
2.48

Sales & Book Value

Annual Sales
$26.58 billion
Price / Sales
5.33
Cash Flow
$23.97 per share
Price / Cash Flow
11.04
Book Value
$6.86 per share
Price / Book
38.58

Miscellaneous

Outstanding Shares
534,901,000
Free Float
531,852,000
Market Cap
$141.55 billion
Optionable
Optionable
Beta
0.61

Social Links

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Robert A. BradwayMr. Robert A. Bradway (Age 60)
    Chairman, CEO & Pres
    Comp: $5.49M
  • Mr. Peter H. GriffithMr. Peter H. Griffith (Age 64)
    Exec. VP & CFO
    Comp: $2.57M
  • Mr. Esteban Santos (Age 55)
    Exec. VP of Operations
    Comp: $2.52M
  • Dr. David M. Reese M.D. (Age 60)
    Exec. VP of R&D
    Comp: $2.83M
  • Mr. Murdo GordonMr. Murdo Gordon (Age 56)
    Exec. VP of Global Commercial Operations
    Comp: $2.72M
  • Mr. Matthew C. Busch (Age 49)
    Chief Accounting Officer & VP of Fin.
  • Mr. Mike Zahigian
    Sr. VP & Chief Information Officer
  • Mr. Arvind Sood
    VP of Investor Relations
  • Mr. Jonathan P. GrahamMr. Jonathan P. Graham (Age 62)
    Exec. VP, Gen. Counsel & Sec.
  • Ms. Nancy A. GrygielMs. Nancy A. Grygiel (Age 55)
    Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AMGN Stock - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 2 sell ratings, 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings or view top-rated stocks.

What is Amgen's stock price forecast for 2023?

15 analysts have issued 12 month price targets for Amgen's stock. Their AMGN share price forecasts range from $200.00 to $320.00. On average, they expect the company's stock price to reach $265.44 in the next year. This suggests a possible upside of 0.3% from the stock's current price.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2023?

Amgen's stock was trading at $262.64 on January 1st, 2023. Since then, AMGN shares have increased by 0.8% and is now trading at $264.74.
View the best growth stocks for 2023 here.

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AMGN earnings forecast.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings data on Thursday, August, 3rd. The medical research company reported $5.00 EPS for the quarter, topping the consensus estimate of $4.44 by $0.56. The medical research company earned $7 billion during the quarter, compared to the consensus estimate of $6.66 billion. Amgen had a net margin of 30.02% and a trailing twelve-month return on equity of 196.60%. The firm's quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.65 EPS.
Read the conference call transcript.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Tuesday, August 1st. Investors of record on Friday, August 18th will be paid a dividend of $2.13 per share on Friday, September 8th. This represents a $8.52 annualized dividend and a yield of 3.22%. The ex-dividend date of this dividend is Thursday, August 17th.
Read our dividend analysis for AMGN.

What ETFs hold Amgen's stock?

ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include Timothy Plan Market Neutral ETF (TPMN), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Pharmaceuticals ETF (PJP), FT Cboe Vest DJIA Dogs 10 Target Income ETF (DOGG) and Invesco Dow Jones Industrial Average Dividend ETF (DJD).

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $8.52 per share and currently has a dividend yield of 3.15%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 57.45%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.75% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY23 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $17.80-$18.80 for the period, compared to the consensus estimate of $17.73. The company issued revenue guidance of $26.6-$27.4 billion, compared to the consensus revenue estimate of $27.02 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $264.74.

How much money does Amgen make?

Amgen (NASDAQ:AMGN) has a market capitalization of $141.61 billion and generates $26.58 billion in revenue each year. The medical research company earns $6.55 billion in net income (profit) each year or $14.83 on an earnings per share basis.

How many employees does Amgen have?

The company employs 25,200 workers across the globe.

Does Amgen have any subsidiaries?
The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.

This page (NASDAQ:AMGN) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -